These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 17630837)

  • 1. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
    Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
    Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
    Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
    Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
    Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
    Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
    Van Houdt WJ; Haviv YS; Lu B; Wang M; Rivera AA; Ulasov IV; Lamfers ML; Rein D; Lesniak MS; Siegal GP; Dirven CM; Curiel DT; Zhu ZB
    J Neurosurg; 2006 Apr; 104(4):583-92. PubMed ID: 16619663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
    Zhu ZB; Makhija SK; Lu B; Wang M; Wang S; Takayama K; Siegal GP; Reynolds PN; Curiel DT
    J Thorac Oncol; 2006 Sep; 1(7):701-11. PubMed ID: 17409940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.
    Nandi S; Ulasov IV; Rolle CE; Han Y; Lesniak MS
    J Gene Med; 2009 Nov; 11(11):1005-11. PubMed ID: 19688792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.
    Zheng S; Ulasov IV; Han Y; Tyler MA; Zhu ZB; Lesniak MS
    J Gene Med; 2007 Mar; 9(3):151-60. PubMed ID: 17351980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.
    Ulasov IV; Rivera AA; Sonabend AM; Rivera LB; Wang M; Zhu ZB; Lesniak MS
    Cancer Biol Ther; 2007 May; 6(5):679-85. PubMed ID: 17404502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
    Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
    Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy.
    Li X; Mao Q; Wang D; Xia H
    Int J Oncol; 2012 Dec; 41(6):2159-65. PubMed ID: 23117867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
    Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
    Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
    He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
    Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy.
    Ulasov IV; Tyler MA; Zhu ZB; Han Y; He TC; Lesniak MS
    Int J Oncol; 2009 Mar; 34(3):729-42. PubMed ID: 19212678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells.
    Nandi S; Ulasov IV; Tyler MA; Sugihara AQ; Molinero L; Han Y; Zhu ZB; Lesniak MS
    Cancer Res; 2008 Jul; 68(14):5778-84. PubMed ID: 18632631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
    Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
    Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.